Today is #RareDiseaseDay — a time to raise awareness, celebrate resilience, and advocate for those living with rare conditions like Ataxia-Telangiectasia. At Quince, we’re committed to advancing treatments that make a difference.? ? Learn more here:?https://lnkd.in/e6Sy6-a8????
Quince Therapeutics
生物技术研究
South San Francisco，California 3,009 位关注者
Dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases
关于我们
Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. Our Phase 3 lead asset, EryDex, is the first product in development that leverages our proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. Red blood cells have several characteristics that make them a potentially effective vehicle for drug delivery, including potentially better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life. Quince’s AIDE technology is designed to harness these benefits to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. EryDex is composed of dexamethasone sodium phosphate (DSP) encapsulated in autologous red blood cells targeted to treat a rare pediatric neurodegenerative disease called Ataxia-Telangiectasia, or A-T. We are currently enrolling the pivotal Phase 3 NEAT study, which is an international, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the neurological effects of EryDex in patients with A-T. The Phase 3 NEAT trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA), and we expect to report topline results in the fourth quarter of 2025 with a potential New Drug Application (NDA) submission to the FDA and a Marketing Authorization (MAA) submission to the European Medicines Agency (EMA) in 2026, assuming positive study results. Additionally, Quince was granted Fast Track designation by the FDA for the company’s EryDex System for the treatment of patients with A-T based on the potential for EryDex to address A-T's high unmet need.
- 网站
-
https://www.quincetx.com
Quince Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- South San Francisco，California
- 类型
- 上市公司
- 创立
- 2012
地点
-
主要
获取路线
611 Gateway Blvd
Suite 273
US，California，South San Francisco，94080
Quince Therapeutics员工
动态
-
Investor Webinar Reminder: Please be certain to join Quince as we will host an investor webinar beginning at 10 a.m. Eastern Time today featuring key opinion leader Dr. Mary Kay Koenig (UTHealth Houston) for a discussion focused on addressing the high unmet need in Ataxia-Telangiectasia. Please register here: https://lnkd.in/gWZWdMqj. We also provided an update on our Phase 3 NEAT clinical trial, which is nearing 50% enrollment with 46 participants to date, in addition to reiterating expectation of enrollment completion in the second quarter of 2025 and topline results in the fourth quarter of 2025. Read more here: https://lnkd.in/gcpnHYFh.?
-
-
Save the Date: Quince looks forward to presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference taking place virtually on February 12th beginning at 2:00 p.m. Eastern Time. Listen in here: https://lnkd.in/g9cfg4zC
-
-
Quince is pleased to announce that the U.S. Patent and Trademark Office has issued a Notice of Allowance that strengthens our market exclusivity and extends the company’s patent claims to 2036 in the U.S. This newly allowed application covers the method of treating patients with Ataxia-Telangiectasia and provides patent coverage for preparing erythrocytes loaded with one or more substances of pharmaceutical interest using the EryDex process. Read more here: https://lnkd.in/gbXjxfvB
-
-
We invite you to join us for an exclusive KOL event focused on addressing the high unmet need in Ataxia-Telangiectasia (A-T)! Mary Kay Koenig and Dirk Thye, MD will discuss the latest insights, emerging research, and potential therapeutic strategies to improve patient outcomes, including Quince's ongoing Phase 3 trial. Don’t miss this opportunity to engage with thought leaders driving progress in A-T care, sign up today!
此处无法显示此内容
在领英 APP 中访问此内容等
-
Save the Date: Quince will host an investor webinar on Friday, February 7th beginning at 10 a.m. Eastern Time featuring key opinion leader Dr. Mary Kay Koenig from UTHealth Houston with a discussion focused on addressing the high unmet need in Ataxia-Telangiectasia. Please register here: https://lnkd.in/gWZWdMqj
-
-
Quince is pleased to announce the publication of long-term safety data from patients with A-T treated with EryDex for a minimum of 24 months in scientific journal Frontiers in Neurology. Read more here: https://lnkd.in/gin_33AY ???????
-
-
Quince is pleased to announce the appointment of renowned pediatric neurologist and expert in ataxia-telangiectasia Dr. William Whitehouse from the University of Nottingham and Nottingham Children’s Hospital to Quince’s Scientific Advisory Board. Read more here: https://lnkd.in/gWYp9nBV #biotech #raredisease #innovation?
-
-
Today, Quince provided a third quarter 2024 business update detailing our latest clinical, scientific, and corporate activities. Read more in the news release here: https://lnkd.in/gig4BK9s
-
Quince is pleased to participate at the 2024 International Congress for Ataxia Research with two poster presentations featuring data from our prior Phase 3 ATTeST study describing growth and bone mineral density in patients with A-T treated with EryDex and validation of the primary efficacy endpoint utilized in the study. View our poster here: https://lnkd.in/gJh8jsTf